Special Issue "Glycomimetics and Glycoconjugates in Drug Discovery"
Deadline for manuscript submissions: closed (31 January 2022) | Viewed by 19021
Interests: organic chemistry; medicinal chemistry; carbohydrate and nucleos(t)ide chemistry; bioactive molecules; enzyme inhibitors; anticancer agents; antimicrobial agents; anti-Alzheimer’s agents
Special Issues, Collections and Topics in MDPI journals
Special Issue in Antibiotics: Carbohydrate-Based Strategies in Antimicrobial Research
Topical Collection in Drugs and Drug Candidates: Carbohydrate-Containing Molecules: A Platform of Opportunities for Drug Discovery
Special Issue in Pharmaceuticals: The 20th Anniversary of Pharmaceuticals—Emerging Trends in Biopharmaceuticals
Interests: bioconjugate vaccines; carbohydrate and nucleos(t)ide chemistry; small-molecule libraries; tumor-associated carbohydrate antigens; enzyme inhibition; anti-infectious disease; anticancer agents; chemical biology; glycoscience
Glycoconjugates are involved in important biological processes, acting in cell recognition and adhesion events through carbohydrate–protein interactions which are crucial for the recognition of pathogens (viruses, bacteria, parasites) by the host and the progression of infection. Glycoconjugates also play relevant roles in human diseases characterized by abnormal glycosylation, such as in cancer, where aberrant cell surface glycoconjugates contribute to tumor progression and metastasis. Therefore, targeting enzymes that are involved in the glycosylation processes leading to disease-associated glycoconjugates by using glycoconjugate and carbohydrate mimetics as well as developing glycomimetics able to inhibit protein–carbohydrate interactions are promising strategies in drug discovery. Carbohydrate-acting enzymes are also important therapeutic targets for metabolic disorders, such as diabetes and lysosomal diseases, and various glycomimetic-based small-molecule inhibitors have found clinical application. On the other hand, the glycoconjugation of various bioactive molecules is a demonstrated approach for obtaining compounds with improved efficacy and lower toxicity. Driven by the increasing interest in the development of novel glycoconjugates and glycomimetic lead compounds of pharmaceutical interest, this Special Issue welcomes contributions demonstrating the continuous importance of these groups of molecules in medicinal glycochemistry and will highlighting recent advances in this topic.
Dr. Nuno Manuel Xavier
Prof. Peter R. Andreana
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- carbohydrate–protein interactions
- carbohydrate-acting enzymes
- medicinal glycochemistry
- drug design
- drug discovery